Method for activating t-cells
AssigneesTakeda Pharmaceutical Company Limited, Noile-Immune Biotech, Inc.
InventorsSoichiro OGAKI, Hideo ARAKI, Eiki MAEDA
Life of this patent
Estimating the term…
Loading patent…
AssigneesTakeda Pharmaceutical Company Limited, Noile-Immune Biotech, Inc.
InventorsSoichiro OGAKI, Hideo ARAKI, Eiki MAEDA
Estimating the term…
Provided is a method for activating T cells comprising the step of activating T cells in a medium containing a CD3 agonist and/or a CD28 agonist for more than 36 hours and less than 48 hours; a method for producing genetically modified T cells, comprising the steps of activating T cells according to the activation method, introducing an exogenous gene into the activated T cells, and culturing the T cells into which the exogenous gene has been introduced; a cell population comprising genetically modified T cells obtained by the production method; and a matrix of mobile polymer chains or a bead supporting a CD3 agonist and/or a CD28 agonist, wherein the matrix or bead is used for being added to a medium and subjecting T cells to an activation step for more than 36 hours and less than 48 hours.
A method for activating T cells comprising the step of activating T cells in a medium containing a CD3 agonist and/or a CD28 agonist for more than 36 hours and less than 48 hours.
A matrix of mobile polymer chains or a bead supporting a CD3 agonist and/or a CD28 agonist, wherein the matrix or bead is used for being added to a medium and subjecting T cells to an activation step for more than 36 hours and less than 48 hours.
A T-cell activation kit for introducing an exogenous gene, comprising
Dependencies are inferred from the claim text.